We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 109

Federal Court of Appeal holds PMNOC appeal moot - innovator argument on CETA equal access to appeal right rejected

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • February 12 2015

Janssen Inc. et al. (Janssen) appealed from the decision of Justice Barnes of the Federal Court refusing to prohibit the Minister of Health from

Federal Court rejects generic’s non-infringing alternative defence and awards compound interest for patent infringement damages

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • February 2 2015

On January 23, 2015, the Federal Court released its public reasons for Judgment granting Eli Lilly and Company and Eli Lilly Canada, Inc

Generic companies seek leave to appeal to the Supreme Court of Canada on the “promise of the patent”

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • January 9 2015

On December 23, 2014, Apotex Inc. and Mylan Pharmaceuticals ULC each filed Supreme Court of Canada (SCC) applications for leave to appeal the Federal

Cadeau de Noël?

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • December 18 2014

Nous avions parlé dans ce billet des importants changements proposés à la Loi sur les brevets par le projet de loi C-43 ? Eh bien, le projet de loi a

Do patents liquefy stocks? Patents, trade secrets and impacts on the marketplace

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • December 5 2014

Intellectual Property professionals, and owners of intellectual property (IP) rights, generally agree on the important value of patents. A relevant

Patent term restoration for Canadian pharmaceutical patents

  • Norton Rose Fulbright LLP
  • -
  • Canada, European Union
  • -
  • November 28 2014

The signature of the free-trade agreement texts between Canada and the European Union provided additional details on the provisions relating to the

New developments on the patent “utility” debate in Canada

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

There have been a number of notable developments in recent weeks in respect of patent utility law in Canada

Punitive damages not available under section 8 of the PM (NOC) Regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

The Supreme Court of Canada has refused Teva’s application for leave to appeal the decision of the Federal Court of Appeal which had upheld an order

Canada catching up with the world? Parliament proposes changes to its patent and design laws

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 11 2014

On October 23, 2014, the Canadian Government introduced an omnibus budget bill. The Bill, which implements various tax measures and amends several

STELARA injunction overturned: biologics infringementinvalidity action is remitted back to the Federal Court for a new trial before a different judge

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 3 2014

The Federal Court of Appeal allowed Janssen’s appeals of three decisions of Mr. Justice Hughes that resulted in an injunction order against Janssen